arrow
F

Fabian Acker

Goethe University Frankfurt
H指数:8
被引数:385

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Visual extraction of individual patient data from published kaplan-meier survival plots using a web-based application offering different reconstruction methods (V-Exploder)

使用基于Web的应用程序(V-Exploder)及不同的重建方法从已发布的Kaplan-Meier生存曲线图中提取个体患者数据

2026-10-050
OAAI
Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany

德国真实世界证据:化疗联合放疗后复发NSCLC的临床管理与结局:度伐利尤单抗巩固治疗后的情况

2026-07-230
PRE
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)

预测非癌基因成瘾非小细胞肺癌患者发生脑转移的个体风险:来自德国前瞻性CRISP登记研究(AIO-TRK-0315)的真实世界数据

2026-03-010
OAAI
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

曲妥珠单抗德鲁替康(Trastuzumab Deruxtecan)在HER2突变非小细胞肺癌患者中的全身及颅内疗效与安全性:来自TRACER/HERTras真实世界队列的证据

2026-02-240
OAAI
Pretransplant HMA and Venetoclax in AML patients – a Real-World Analysis from the Cooperative Transplant Study Group

移植前HMA和Venetoclax在AML患者中的应用——来自合作移植研究组的真实世界分析

2025-12-150
OAAI
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer

NeoTRACE试验的研究设计与原理:一项多中心II期研究,评估新辅助沙库巴曲舒坦联合吉米单抗,随后进行辅助吉米单抗联合或不联合沙库巴曲舒坦在可切除非小细胞肺癌患者中的应用。

2025-11-210
PRE
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
2023-09-220
OAAI
Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment
2022-11-018
PRE
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
2022-06-0412
OAAI
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
2021-07-0159
OA